Pharmacy regulator proposes 7.5% increase in registration renewal fees from 2024 Following a freeze in registration fees for two years, the General Pharmaceutical Council has noted that its proposed increases are below inflation.…
Oxybutynin to remain prescription-only medicine, following MHRA consultation The medicines regulator said "overwhelming responses" to its consultation contributed to its decision against reclassification.…
The commission on pharmacy leadership’s proposals threaten the very future it wants In their current form, proposals for the new commission on pharmacy leadership could lead us down a dangerously rocky road, says Mike Hannay.…
CQC says it is reviewing concerns about major homecare medicines provider A spokesperson for the regulator said inspectors are currently reviewing concerns raised about Sciensus and will determine whether regulatory action is required.…
Medicines regulator issues advice to prevent severe harm from JAK inhibitors The Medicines and Healthcare products Regulatory Agency has advised against prescribing janus kinase inhibitors in patients with certain risk factors.…
Two prescribers must agree that acne is ‘severe enough’ before under-18s are prescribed isotretinoin, review concludes The Commission on Human Medicines' recommendations will be taken forward by the Medicines and Healthcare products Regulatory Agency to support the acne drug's safe use.…
The Great Nitrosamine Audit: how many more drugs will disappear from our shelves? Several medicines have already fallen foul of the ongoing review into the presence of possible carcinogens and experts say it could pose “an existential threat” to many others.…
European regulator finds at least 20 medicines with significant nitrosamine contamination Exclusive: The European Medicines Agency has said products identified as containing nitrosamine above acceptable levels will likely require a variation in their marketing authorisation.…
Medicines regulator approves UK’s first dual combination inhaler for mild asthma AstraZeneca said the marketing authorisation meant its Symbicort Turbohaler 200/6 could be used by 2.7 million adults in the UK who live with mild asthma.…
Epilepsy charities call on government to immediately halt two-clinician sign-off for patients taking valproate A coalition of epilepsy charities has said the decision is "totally out of proportion to the risks to patient safety".…